Assuntos
Análise Custo-Benefício , Fibrose Cística , Medicamentos Genéricos , Fibrose Cística/tratamento farmacológico , Fibrose Cística/economia , Humanos , Medicamentos Genéricos/economia , Aminofenóis/economia , Aminofenóis/uso terapêutico , Benzodioxóis/economia , Benzodioxóis/uso terapêutico , Quinolonas/economia , Quinolonas/uso terapêutico , Custos de Medicamentos , Aminopiridinas/economia , Aminopiridinas/uso terapêutico , Combinação de Medicamentos , Análise de Custo-EfetividadeRESUMO
In this latest update, we look at recent developments in market access including the pricing agreement of Libmeldy® by the Beneluxa Initiative, the financial impact of managed entry agreements in Italy and the restructuring of Agenzia Italiana del Farmaco (AIFA). We also highlight the collaboration between FINOSE and the New Expensive Drug (NED) section of the Nordic Pharmaceutical Forum.
Assuntos
Avaliação da Tecnologia Biomédica , Humanos , Avaliação da Tecnologia Biomédica/métodos , Itália , Acessibilidade aos Serviços de Saúde , Custos de Medicamentos/tendênciasRESUMO
In this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.
Assuntos
Academias e Institutos , Tecnologia Biomédica , Humanos , Análise Custo-Benefício , FrançaRESUMO
In this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to treatment.